Preaxia Health Care Pymnt (PAXH) Financials
Newest figures come from the 10-Q for Q1 FY2027, filed Oct 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PAXH SEC filings page.
Preaxia Health Care Pymnt (PAXH) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2026 shows a development-stage operation: external financing funded investment while accounting losses remained much larger than operating cash outflow.
In FY2026, a net loss of$1.16M coexisted with operating cash flow of-$121K , so reported earnings were not translating into equivalent cash use. This earnings-to-cash gap points to accounting items or working-capital effects that did not immediately consume cash, although the reported figures do not identify the mix.
The latest cost structure is development-led: research and development was
The balance sheet is structurally strained: liabilities of
Financial Health Signals
We do not publish a peer-relative financial health score for Preaxia Health Care Pymnt, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Preaxia Health Care Pymnt reported a net loss of $1.2M while operations used $121K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Preaxia Health Care Pymnt reported an operating loss of $993K against $326 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Preaxia Health Care Pymnt generated $0 in revenue in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Preaxia Health Care Pymnt's EBITDA was -$183K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Preaxia Health Care Pymnt reported a net loss of $207K in Q1 2027.
Preaxia Health Care Pymnt earned $0.00 per diluted share (EPS) in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Preaxia Health Care Pymnt recorded an outflow of $78K in free cash flow in Q1 2027, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Preaxia Health Care Pymnt held $142K in cash against $50K in long-term debt as of Q1 2027, with $1.3M of liabilities due within a year.
Not reported for Q1 2027.
Margins & Returns
None of these metrics is reported for Q1 2027.
Capital Allocation
Preaxia Health Care Pymnt reported no research and development spending in Q1 2027. This represents a decrease of 100.0% from the same quarter a year earlier.
Preaxia Health Care Pymnt invested $100K in capex in Q1 2027, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 11.9%.
Not reported for Q1 2027.
PAXH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q/A | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m | $0n/m |
| R&D Expenses | $0-100.0% | N/A | $0n/m | $0n/m | $308Kn/m | N/A | $0-100.0% | $0-100.0% |
| SG&A Expenses | $67K+337.1% | N/A | $5K | $5K | $15K | N/A | N/A | N/A |
| Operating Income | -$200Kn/m | N/A | -$95K | -$112K | -$576K | N/A | N/A | N/A |
| EBITDA | -$183Kn/m | N/A | -$95K | N/A | -$576K | N/A | N/A | N/A |
| Interest Expense | $6K+49861.5% | N/A | $0 | $0n/m | $13n/m | N/A | N/A | $0 |
| Income Tax | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m | $0 |
| Net Income | -$207K | N/A | -$94K | -$112K | N/A | N/A | N/A | N/A |
| EPS (Basic) | $0.00n/m | -$0.01 | $0.00 | $0.00 | -$0.02 | $0.00n/m | $0.00n/m | $0.00n/m |
| EPS (Diluted) | $0.00n/m | -$0.01 | $0.00 | $0.00 | -$0.02 | $0.00n/m | $0.00n/m | $0.00n/m |
| Diluted Shares (Avg) | 47M+34.8% | N/A | 44M | 44M | 35M | N/A | 20M0.0% | 20M0.0% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
PAXH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q/A | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $836K+541.8% | $584Kn/m | $443K+14759233.3% | $144K+86952.1% | $130K+13028400.0% | $0-100.0% | $3-99.7% | $165-91.2% |
| Current Assets | $142K+8.7% | $1Kn/m | $57K+1910900.0% | $14K+8291.5% | $130K+13028400.0% | $0-100.0% | $3-99.7% | $165-91.2% |
| Cash & Equivalents | $142K+8.7% | $1Kn/m | $57K+1910900.0% | $14K+8291.5% | $130K+13028400.0% | $0-100.0% | $3-99.7% | $165-91.2% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.4M+87.4% | $967K-58.7% | $807K-66.7% | $769K-68.2% | $736K-69.3% | $2.3M-2.3% | $2.4M+1.3% | $2.4M+1.3% |
| Current Liabilities | $1.3M+80.6% | $967K-58.7% | $807K-66.8% | $769K-68.2% | $736K-69.3% | $2.3M-2.3% | $2.4M+1.5% | $2.4M+1.3% |
| Non-Current Liabilities | $50Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | -$4Kn/m | $0n/m |
| Long-Term Debt | $50K | $0 | $25K | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$543Kn/m | -$384Kn/m | -$364Kn/m | -$625Kn/m | -$608Kn/m | -$2.3Mn/m | -$2.4Mn/m | -$2.4Mn/m |
| Retained Earnings | -$6.6Mn/m | -$6.4Mn/m | -$6.2Mn/m | -$6.1Mn/m | -$6.0Mn/m | -$5.2Mn/m | -$5.2Mn/m | -$5.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
PAXH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q/A | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $22Kn/m | -$13Kn/m | $5K | -$39K | -$75K | -$18K | N/A | N/A |
| Depreciation & Amortization | $17Kn/m | N/A | $0n/m | N/A | $0 | N/A | $0 | N/A |
| Capital Expenditures | $100Kn/m | $114Kn/m | $137Kn/m | $71K | $0 | $0 | $0 | N/A |
| Free Cash Flow | -$78Kn/m | -$126Kn/m | -$132K | -$110K | -$75K | -$18K | N/A | N/A |
| Investing Cash Flow | -$100Kn/m | -$114Kn/m | -$137Kn/m | -$71Kn/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Financing Cash Flow | $233K+15.2% | $68K+331.8% | $176K | -$464 | $202K | $16K | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
PAXH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$384K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Preaxia Health Care Pymnt PAXH | FY2026 | $0 | -$1.2M | N/A | N/A | — |
| Pharm-Bio Serv Inc PBSV | FY2025 | $9.0M | -$100K | -1.1% | $11.9M | — |
| Vaso Corporation VASO | FY2025 | $89.1M | $1.6M | 1.8% | $51.4M | — |
| Veradigm Inc MDRX | FY2024 | $594.4M | -$291.5M | -49.0% | $536.8M | — |
Where Preaxia Health Care Pymnt Ranks
Frequently Asked Questions
Preaxia Health Care Pymnt (PAXH) reported $0 in total revenue for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Preaxia Health Care Pymnt (PAXH) reported a net loss of $1.2M in fiscal year 2026.
Preaxia Health Care Pymnt (PAXH) had EBITDA of -$976K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2026, Preaxia Health Care Pymnt (PAXH) had $1K in cash and equivalents against $0 in long-term debt.
Preaxia Health Care Pymnt (PAXH) recorded an outflow of $443K in free cash flow during fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Preaxia Health Care Pymnt (PAXH) recorded an outflow of $121K in operating cash flow during fiscal year 2026, representing cash used by core business activities.
Preaxia Health Care Pymnt (PAXH) had $584K in total assets as of fiscal year 2026, including both current and long-term assets.
Preaxia Health Care Pymnt (PAXH) invested $322K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
Preaxia Health Care Pymnt (PAXH) invested $308K in research and development during fiscal year 2026.
Preaxia Health Care Pymnt (PAXH) had a current ratio of 0.00 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
Preaxia Health Care Pymnt (PAXH) had a return on assets of -199.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2026, Preaxia Health Care Pymnt (PAXH) held $1K in cash, cash equivalents and investments, and reported an operating cash outflow of $121K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Preaxia Health Care Pymnt (PAXH) has negative shareholder equity of -$384K as of fiscal year 2026, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Preaxia Health Care Pymnt (PAXH) reported a net loss of $1.2M while operations used $121K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Preaxia Health Care Pymnt (PAXH) reported an operating loss of $993K against $326 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.